Switching or Transitioning Between Hims vs Ro vs Calibrate: Questions to Ask a Prescriber
Treat a switch as a continuity problem first. The risks that actually materialize are a gap in supply between the last shipment and the first new one, a new clinician restarting titration from the bottom, and two memberships billing at once. Price is the easiest part to compare and the least likely to cause harm. Ask about dose carryover before anything else.
Will the new prescriber start where the old one left off
This is the question that decides whether a switch costs weeks of progress. A clinician taking over care is not obliged to continue a dose they did not set, and starting again at an introductory step means repeating the titration period and its side effects. Some will continue an established dose with documentation, some will step back one level, and some will restart.
Documentation is what makes the conversation easy. Pharmacy records showing dispensed strengths and dates, plus a summary of tolerability at each step, give a new prescriber something to act on. A verbal description of a dose does not. Ask the outgoing program for a written medication history before canceling, because access to a patient portal often ends when billing does.
Switching product form is a labeled procedure, not an improvisation
Transitions between forms of the same molecule are addressed in the prescribing information itself. The current Wegovy label covers both injection and tablet presentations and contains a dedicated section on switching between them, with specified dose correspondences in each direction and guidance on what to do when a maintenance dosage is not tolerated. The same label sets out what to do about missed doses, which differs between the weekly injection and the daily tablet.
Labels in this class also carry a limitation of use stating that concomitant use with other products containing the same molecule, or with any other GLP-1 receptor agonist, is not recommended. That matters during a handover, because the failure mode is overlap rather than shortage: a final shipment from the old program arriving after the new one has already dispensed. Confirm the intended stop date for the first prescription in writing.
Some providers now publish switching guidance directly, which is worth reading before the first call. HealthRX, for instance, maintains a page on switching GLP-1 medications that walks through dose mapping between agents, while Ro and Hims and Hers handle the same conversation through a clinician message and LillyDirect defers to the approved label. Comparing how openly each one addresses a change of drug tells a patient something about how a mid-course adjustment is likely to be handled later.
Coverage records do not transfer automatically
Anyone leaving a program that secured a prior authorization is leaving behind work rather than a portable asset. Calibrate builds insurance navigation into its membership, and Ro publishes an insurance concierge that files prior authorization paperwork, so both hold documentation that a new prescriber will otherwise have to reassemble. Approvals are usually tied to the prescriber and the plan year, and a new prescriber generally triggers a fresh submission.
Ask for copies of the approval letter, the documented diagnosis codes, any step-therapy record showing previously tried agents, and the dates the authorization runs through. Ask the incoming program how long its own authorization process takes and whether it will supply a self-pay bridge in the meantime. For someone leaving coverage behind entirely, a flat monthly cash program such as those published by Henry Meds, Mochi Health or a physician-supervised GLP-1 provider with a single stated price removes the authorization variable altogether, at the cost of moving to compounded preparations that the FDA has not reviewed for safety, effectiveness or manufacturing quality.
| Transition item | What to ask the outgoing program | What to ask the incoming program
|
|---|---|---|
| Dose history | Written record of strengths and dispense dates | Whether the current dose will be continued |
| Final shipment | Exact date the last order ships | Earliest date the first order can ship |
| Prior authorization | Copy of the approval and its end date | Whether a new submission is required |
| Product form | Which presentation and strength is current | Whether the same form is available |
| Billing overlap | The action that stops the recurring charge | Whether the first charge can be delayed |
| Prepaid balance | What happens to unused prepaid months | Whether a month-to-month start is offered |
Commitment terms decide how expensive the overlap gets
Exit terms differ in shape across these services. Calibrate’s published pricing sets an initial multi-month commitment before month-to-month cancellation becomes available. Ro publishes prepaid twelve-month, six-month and three-month plans priced below its month-to-month rate, which means an early departure forfeits value that has already been paid. Hims and Hers uses a discounted first month followed by a recurring rate.
None of that is unusual for subscription telehealth, and all of it is knowable before signing up. The practical move is to time a switch to a renewal boundary rather than to the middle of a prepaid block, and to confirm in writing exactly which action stops billing. Canceling inside an app is not always the same as canceling a clinical enrollment.
Pausing is a clinical decision, not just a billing one
Some people switch programs when what they actually want is to stop treatment. The evidence on that is worth knowing before the decision is made rather than after. A published extension of a large semaglutide trial documented weight regain and reversal of cardiometabolic improvements after withdrawal, continuation trials for both semaglutide and tirzepatide examined maintenance versus discontinuation, and a 2026 review examined the causes and consequences of stopping this class of therapy in depth.
If the goal is a break rather than a change of vendor, that is a conversation to have with the prescriber who knows the dose history, ideally before the last shipment has already been used.
Frequently asked questions
Can a new program continue an existing dose immediately?
Sometimes, and it depends on the clinician and on the documentation supplied. Pharmacy records showing dispensed strengths and dates make continuation far more likely than a self-reported dose. Where records are missing, expect a conservative restart, which means repeating part of the titration period and the side effects that accompany it.
What is the safest way to avoid a supply gap?
Line up the incoming program’s first shipment date before canceling the outgoing one, and confirm both dates in writing. Overlap is the more common failure than shortage, so also confirm that no further order will ship from the old program, since labeling in this class advises against concurrent use of two GLP-1 receptor agonists.
Does a prior authorization move with the patient?
Generally no. Approvals are tied to a prescriber, a plan and a time window, so a new prescriber usually files fresh. Requesting the approval letter, diagnosis codes and any documented step-therapy history from the departing program shortens the new submission considerably and can prevent a repeat of failed-therapy requirements.
Is switching from a brand product to a compounded one straightforward?
It changes more than the price. Compounded preparations are not FDA-approved, are frequently supplied in vials measured by the patient rather than in prefilled pens, and carry no approved labeling to map dose equivalence. A prescriber should set the dose explicitly rather than assuming a direct transfer from a brand strength.
